Keywords: Mycobacterium abscessus complex, Mycobacterium abscessus, Mycobacterium massiliense, Mycobacterium bolletii, multidrug resistant, nontuberculous, mycobacteria, outbreaks, cosmetic procedures, nosocomial, transmission, taxonomy, nomenclature, clinical disease, bacteria, identification methods

Bacterial Classification

M. abscessus was first isolated from a knee abscess in 1952 (1).M. abscessus andM. chelonae were originally considered to belong to the same species (“M. chelonei” or “M. chelonae”), but in 1992,M. abscessus was reclassified as an individual species (1). AfterM. abscessus was recognized as an independent species, new subspecies, includingM. massiliense andM. bolletii, were discovered. Debate has ensued over whetherM. massiliense andM. bolletii should be reunited to form one subspecies,M. abscessus subsp.bolletii (6). It is hoped that the debate will be settled as a result of findings from several recent studies that clearly demonstrated, by genome comparison, thatM. abscessus complex comprises 3 entities:M. abscessus subsp.abscessus,M. abscessus subsp.massiliense, andM. abscessus subsp.bolletii (7–11). Serial changes in the taxonomic classification and nomenclature ofM. abscessus complex, from 1992 to 2013, are shown inFigure 1.

M. abscessus subsp.bolletii is recognized as a rare pathogen with a functional inducible erythromycin ribosome methyltransferase (erm) (41) gene. In mostM. abscessus subsp.abscessus mycobacterium, this gene leads to macrolide resistance.M. abscessus subsp.massiliense has been proposed to have a nonfunctionalerm(41) gene, leading to macrolide susceptibility and a favorable treatment outcome for infections (7–11).

Laboratory Identification

Definitive diagnosis ofM. abscessus complex infection in humans is invariably determined by the isolation ofM. abscessus complex from clinical specimens. The correct subspecies identification ofM. abscessus complex has traditionally relied on phenotypic methods (e.g., biochemical testing for the utilization of citrate) to distinguish them from closely related species likeM. chelonae (1). However, this method is not accurate enough to differentiate between the 2 main subspecies of the complex. Instead,rpoB gene–based sequencing is a more reliable method for correctly identifyingM. abscessus complex to the subspecies level (10). However, because of the limited differences between the subspecies ofM. abscessus complex, some researchers have questioned the accuracy of identification results from the sequencing of a single gene, especially therpoB gene (10). Many schemes have been used in an attempt to accurately differentiate between subspecies, such as multilocus gene sequence typing, sequencing of theerm gene, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Figure 2) (10,12). Nonetheless, because the taxonomic classification is still changing, the debate over the optimal identification method will probably also continue.

Respiratory Tract Infections

M. abscessus complex can cause pulmonary disease, especially in vulnerable hosts with underlying structural lung disease, such as cystic fibrosis, bronchiectasis, and prior tuberculosis (2).M. abscessus complex pulmonary disease usually follows an indolent, but progressive, course, causing persistent symptoms, decline of pulmonary function, and impaired quality of life; however, the disease can also follow a fulminant course with acute respiratory failure (2,14). Establishing a diagnosis of pulmonary disease due toM. abscessus complex is not straightforward because isolation ofM. abscessus complex from respiratory samples is not, in and of itself, diagnostic of pulmonary disease (2). According to guidelines published by the American Thoracic Society/Infectious Diseases Society of America in 2007, the diagnosis ofM. abscessus complex pulmonary disease requires the fulfillment of clinical and microbiological criteria, such as the presence of clinical symptoms; radiographic evidence of lesions compatible with NTM pulmonary disease; appropriate exclusion of other diseases; and, in most circumstances, positive culture results from at least 2 separate expectorated sputum samples (2). Common radiographic findings ofM. abscessus complex pulmonary infection (i.e., bronchiolitis; bronchiectasis; nodules; consolidation; and, less frequently, cavities) are shown inFigure 3 (2).

M. abscessus complex is especially prevalent in respiratory specimens from patients with cystic fibrosis (7,15). Recent studies have shown thatM. abscessus complex infection is no longer a contraindication for lung transplantation, although postoperative complications and a prolonged treatment course can be expected (7).

Pulmonary disease caused byM. abscessus complex is notoriously difficult to treat. Although there is no standard treatment, current guidelines suggest the administration of macrolide-based therapy in combination with intravenously administered antimicrobial agents; however, this regimen has been shown to have a substantial cytotoxic effect (2). Of 65 patients with pulmonary disease due toM. abscessus complex who received an initial 4-week course of intravenous antimicrobial agents followed by macrolide-based combination therapy, 38 (58%) hadM. abscessus–negative sputum samples >12 months after treatment (16). Surgical resection of localized disease in addition to antimicrobial therapy has been shown to elicit a longer microbiologic response than antimicrobial agents alone: sputum samples wereM. abscessus complex–negative for at least 1 year in 57% versus 28% of these treatment groups, respectively (17). According to the 2007 American Thoracic Society/Infectious Diseases Society of America guidelines, the treatment options remain limited with current antimicrobial agents, andM. abscessus complex pulmonary disease is still considered a chronic incurable disease (2).

The advancement of subspecies differentiation has allowed for more effective management of pulmonary disease caused byM. abscessus complex. For example, unlikeM. abscessus subsp.abscessus,M. abscessus subsp.massiliense does not have inducible resistance to clarithromycin (7). Therefore, knowing that a patient’s infection is due toM. abscessus subsp.massiliense rather than 1 of the other 2 subspecies enables the physician to confidently administer clarithromycin (7,18). In a large study on treatment outcome in patients with pulmonary disease caused byM. Abscessus subsp.massiliense orM. abscessus subsp.abscessus, all patients had similar clinical signs, radiographic findings, and treatment regimens (18). However, after treatment, the percentage of patients who had negative sputum culture results was much higher in theM. abscessus subsp.massiliense–infected group (88%) than in theM. abscessus subsp.abscessus–infected group (25%) (18). The lack of efficacy of clarithromycin-containing antimicrobial therapy againstM. abscessus subsp.abscessus isolates in the study could be explained by the subspecies’ inducible resistance to clarithromycin. The study clearly demonstrated howM. abscessus subsp.massiliense andM. abscessus subsp.abscessus have different susceptibility profiles to combination therapy containing clarithromycin and different outcomes from such treatment (18).

SSTIs

SSTIs are also commonly caused byM. abscessus complex; infections range from deep tissue infections to localized skin infections. The 2 major mechanisms for acquiring anM. abscessus complex–associated SSTI are by 1) direct contact with contaminated material or water through traumatic injury, surgical wound, or environmental exposure and 2) secondary involvement of skin and soft tissue during disseminated disease (19). SSTIs caused byM. abscessus complex have been reported in patients who recently underwent cosmetic procedures (e.g., mesotherapy), tattooing, and acupuncture (19).M. abscessus complex SSTIs can also develop after exposure to environmental sources, such as spas and hot springs (19,20). More often, however, these SSTIs develop among hospitalized postsurgical patients, in whom surgical wound infections are most commonly due toM. abscessus subsp.massiliense (21,22). DisseminatedM. abscessus complex infections with skin and soft tissue involvement also commonly occur (23). Of note, however, the presence ofM. abscessus complex SSTIs can result in or from disseminatedM. abscessus complex infections (23).M. abscessus complex skin infection have diverse presentations, including cutaneous nodules (usually tender), erythematous papules/pustules, and papular eruptions or abscesses (Figure 4) (19).

Central Nervous System Infections

Central nervous system (CNS) infections caused byM. abscessus complex are rare, but when they do occur, meningitis and cerebral abscesses are the most common manifestations (Figure 5). Although MAC is responsible for most NTM CNS infections, especially in HIV-infected hosts,M. abscessus complex has increasingly been reported to cause CNS infections in HIV-negative patients (21). In one study,M. abscessus was responsible for most NTM CNS infections in HIV-seronegative patients (8/11 patients), especially in patients who had undergone neurosurgical procedures, patients who had intracranial catheters, and patients with otologic diseases. Treatment outcome depended on the patient’s underlying disease and health status. Clarithromycin-based combination therapy for at least 1 year plus surgical intervention, if needed, offered the best chance for cure (21).

Disseminated Diseases and Bacteremia

DisseminatedM. abscessus complex infections, such as lymphadenopathy, SSTIs, pulmonary infections, and bacteremia, are on the rise (23), and bacteremia caused byM. abscessus complex is most often associated with catheter use (24,25). A recent study showed that surgical wound infection may be the portal of entry, especially forM. abscessus subsp.massiliense (26). Optimal treatment modalities include removal of intravascular catheters, surgical debridement, and administration of intravenous antimicrobial agents chosen on the basis of drug susceptibility test results.

DisseminatedM. abscessus complex infections tend to occur in immunocompromised hosts, including persons with HIV. However, these infections can also occur in HIV-negative patients. Browne et al. (23) recently showed that neutralizing anti–interferon-γ autoantibodies were present in 81% of HIV-negative patients with disseminated NTM-associated infections, and in adults, these antibodies were associated with adult-onset immunodeficiency similar to that seen in advanced HIV infection. This adult-onset immunodeficiency status can lead to disseminated NTM disease that mimics advanced HIV infection (23).

Ocular Infections

The incidence of NTM ocular infections (keratitis, endophthalmitis, scleritis, and other tissues of the ocular area) has increased over the past decade, and the increase has been attributed to theM. chelonae/abscessus group (27). Interpreting the real trend in ocular infections caused byM. abscessus complex is difficult because most studies have not used reliable tests to differentiate betweenM. abscessus complex andM. chelonae (27).

Initial treatment ofM. abscessus complex ocular infections involves the discontinuation of topical corticosteroids, if used. The optimal treatment strategy (topical therapy, systemic antimicrobial agents, and surgical intervention) depends on the site of the ocular infection (28). Topical therapy, particularly topical amikacin and clarithromycin, can be used to treat someM. abscessus complex ocular infections (e.g., conjunctivitis, scleritis, keratitis, endophthalmitis) (28), and systemic antimicrobial agents can be used for all ocular infections (28). Surgical debridement, including removal of infected tissue, should be considered and is necessary for treatment of infections in some patients (28). Treatment outcome varies according to the site of infection, and early recognition of the infection is crucial.

Table 1. Summary of recent data on the resistance ofMycobacterium abscessus complex bacteria to different antimicrobial agents*.

Table 2. Summary of recommendations from previous studies for the treatment ofMycobacterium abscessus complex infections in humans.

• 1.Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.Clin Microbiol Rev. 2002;15:716–46. 10.1128/CMR.15.4.716-746.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 2.Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.Am J Respir Crit Care Med. 2007;175:367–416. 10.1164/rccm.200604-571ST [DOI] [PubMed] [Google Scholar]
• 3.Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998–2010.Emerg Infect Dis. 2013;19:1889–91. 10.3201/eid1911.130737 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 4.Lai CC, Tan CK, Chou CH, Hsu HL, Liao CH, Huang YT, et al. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000–2008.Emerg Infect Dis. 2010;16:294–6. 10.3201/eid1602.090675 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 5.Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B.Mycobacterium abscessus: a new antibiotic nightmare.J Antimicrob Chemother. 2012;67:810–8. 10.1093/jac/dkr578 [DOI] [PubMed] [Google Scholar]
• 6.Leao SC, Tortoli E, Euzeby JP, Garcia MJ. Proposal thatMycobacterium massiliense andMycobacterium bolletii be united and reclassified asMycobacterium abscessus subsp.bolletii comb. nov., designation ofMycobacterium abscessus subsp.abscessus subsp. nov. and emended description ofMycobacterium abscessus.Int J Syst Evol Microbiol. 2011;61:2311–3. 10.1099/ijs.0.023770-0 [DOI] [PubMed] [Google Scholar]
• 7.Benwill JL, Wallace RJ Jr.Mycobacterium abscessus: challenges in diagnosis and treatment.Curr Opin Infect Dis. 2014;27:506–10. 10.1097/QCO.0000000000000104 [DOI] [PubMed] [Google Scholar]
• 8.Choo SW, Wee WY, Ngeow YF, Mitchell W, Tan JL, Wong GJ, et al. Genomic reconnaissance of clinical isolates of emerging human pathogenMycobacterium abscessus reveals high evolutionary potential. Sci Rep. 2014;4:4061. [DOI] [PMC free article] [PubMed]
• 9.Cho YJ, Yi H, Chun J, Cho SN, Daley CL, Koh WJ, et al. The genome sequence of ‘Mycobacterium massiliense’ strain CIP 108297 suggests the independent taxonomic status of theMycobacterium abscessus complex at the subspecies level.PLoS ONE. 2013;8:e81560. 10.1371/journal.pone.0081560 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 10.Sassi M, Drancourt M. Genome analysis reveals three genomospecies inMycobacterium abscessus.BMC Genomics. 2014;15:359. 10.1186/1471-2164-15-359 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 11.Heydari H, Wee WY, Lokanathan N, Hari R, Mohamed Yusoff A, Beh CY, et al. MabsBase: aMycobacterium abscessus genome and annotation database.PLoS ONE. 2013;8:e62443. 10.1371/journal.pone.0062443 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 12.Teng SH, Chen CM, Lee MR, Lee TF, Chien KY, Teng LJ, et al. Matrix-assisted laser desorption ionization–time of flight mass spectrometry can accurately differentiate betweenMycobacterium masilliense (M. abscessus subspeciesbolletti) andM. abscessus (sensu stricto).J Clin Microbiol. 2013;51:3113–6. 10.1128/JCM.01239-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 13.Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems.Am J Respir Crit Care Med. 2010;182:970–6. 10.1164/rccm.201002-0310OC [DOI] [PMC free article] [PubMed] [Google Scholar]
• 14.Lee MR, Yang CY, Chang KP, Keng LT, Yen DH, Wang JY, et al. Factors associated with lung function decline in patients with non-tuberculous mycobacterial pulmonary disease.PLoS ONE. 2013;8:e58214. 10.1371/journal.pone.0058214 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 15.Levy I, Grisaru-Soen G, Lerner-Geva L, Kerem E, Blau H, Bentur L, et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel.Emerg Infect Dis. 2008;14:378–84. 10.3201/eid1403.061405 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 16.Jeon K, Kwon OJ, Lee NY, Kim BJ, Kook YH, Lee SH, et al. Antibiotic treatment ofMycobacterium abscessus lung disease: a retrospective analysis of 65 patients.Am J Respir Crit Care Med. 2009;180:896–902 . 10.1164/rccm.200905-0704OC [DOI] [PubMed] [Google Scholar]
• 17.Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment forMycobacterium abscessus pulmonary disease.Clin Infect Dis. 2011;52:565–71. 10.1093/cid/ciq237 [DOI] [PubMed] [Google Scholar]
• 18.Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, et al. Clinical significance of differentiation ofMycobacterium massiliense fromMycobacterium abscessus.Am J Respir Crit Care Med. 2011;183:405–10. 10.1164/rccm.201003-0395OC [DOI] [PubMed] [Google Scholar]
• 19.Kothavade RJ, Dhurat RS, Mishra SN, Kothavade UR. Clinical and laboratory aspects of the diagnosis and management of cutaneous and subcutaneous infections caused by rapidly growing mycobacteria.Eur J Clin Microbiol Infect Dis. 2013;32:161–88 . 10.1007/s10096-012-1766-8 [DOI] [PubMed] [Google Scholar]
• 20.Nakanaga K, Hoshino Y, Era Y, Matsumoto K, Kanazawa Y, Tomita A, et al. Multiple cases of cutaneousMycobacterium massiliense infection in a “hot spa” in Japan.J Clin Microbiol. 2011;49:613–7. 10.1128/JCM.00817-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 21.Lee MR, Cheng A, Lee YC, Yang CY, Lai CC, Huang YT, et al. CNS infections caused byMycobacterium abscessus complex: clinical features and antimicrobial susceptibilities of isolates.J Antimicrob Chemother. 2012;67:222–5. 10.1093/jac/dkr420 [DOI] [PubMed] [Google Scholar]
• 22.Shields RK, Clancy CJ, Minces LR, Shigemura N, Kwak EJ, Silveira FP, et al. Epidemiology and outcomes of deep surgical site infections following lung transplantation.Am J Transplant. 2013;13:2137–45. 10.1111/ajt.12292 [DOI] [PubMed] [Google Scholar]
• 23.Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, et al. Adult-onset immunodeficiency in Thailand and Taiwan.N Engl J Med. 2012;367:725–34. 10.1056/NEJMoa1111160 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 24.El Helou G, Viola GM, Hachem R, Han XY, Raad II. Rapidly growing mycobacterial bloodstream infections.Lancet Infect Dis. 2013;13:166–74. 10.1016/S1473-3099(12)70316-X [DOI] [PubMed] [Google Scholar]
• 25.El Helou G, Hachem R, Viola GM, El Zakhem A, Chaftari AM, Jiang Y, et al. Management of rapidly growing mycobacterial bacteremia in cancer patients.Clin Infect Dis. 2013;56:843–6. 10.1093/cid/cis1032 [DOI] [PubMed] [Google Scholar]
• 26.Lee MR, Ko JC, Liang SK, Lee SW, Yen DH, Hsueh PR. Bacteraemia caused byMycobacterium abscessus subsp.abscessus andM. abscessus subsp.bolletii: clinical features and susceptibilities of the isolates.Int J Antimicrob Agents. 2014;43:438–41. 10.1016/j.ijantimicag.2014.02.007 [DOI] [PubMed] [Google Scholar]
• 27.Girgis DO, Karp CL, Miller D. Ocular infections caused by non-tuberculous mycobacteria: update on epidemiology and management.Clin Experiment Ophthalmol. 2012;40:467–75. 10.1111/j.1442-9071.2011.02679.x [DOI] [PubMed] [Google Scholar]
• 28.Moorthy RS, Valluri S, Rao NA. Nontuberculous mycobacterial ocular and adnexal infections.Surv Ophthalmol. 2012;57:202–35. 10.1016/j.survophthal.2011.10.006 [DOI] [PubMed] [Google Scholar]
• 29.Liu R, To KK, Teng JL, Choi GK, Mok KY, Law KI, et al.Mycobacterium abscessus bacteremia after receipt of intravenous infusate of cytokine-induced killer cell therapy for body beautification and health boosting.Clin Infect Dis. 2013;57:981–91. 10.1093/cid/cit443 [DOI] [PubMed] [Google Scholar]
• 30.Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, et al. Whole-genome sequencing to identify transmission ofMycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study.Lancet. 2013;381:1551–60. 10.1016/S0140-6736(13)60632-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 31.Viana-Niero C, Lima KV, Lopes ML, Rabello MC, Marsola LR, Brilhante VC, et al. Molecular characterization ofMycobacterium massiliense andMycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures.J Clin Microbiol. 2008;46:850–5. 10.1128/JCM.02052-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 32.Clinical and Laboratory Standards Institute (CLSI). Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard—second edition. CLSI document M24–A2. Wayne (PA): The Institute; 2011. [PubMed] [Google Scholar]
• 33.Adékambi T, Drancourt M.Mycobacterium bolletii respiratory infections.Emerg Infect Dis. 2009;15:302–5. 10.3201/eid1502.080837 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 34.Lee SH, Yoo HK, Kim SH, Koh WJ, Kim CK, Park YK, et al. The drug resistance profile ofMycobacterium abscessus group strains from Korea. Ann Lab Med. 2014;34:31–7. [DOI] [PMC free article] [PubMed]
• 35.Huang YC, Liu MF, Shen GH, Lin CF, Kao CC, Liu PY, et al. Clinical outcome ofMycobacterium abscessus infection and antimicrobial susceptibility testing.J Microbiol Immunol Infect. 2010;43:401–6. 10.1016/S1684-1182(10)60063-1 [DOI] [PubMed] [Google Scholar]
• 36.Brown-Elliott BA, Mann LB, Hail D, Whitney C, Wallace RJ Jr. Antimicrobial susceptibility of nontuberculous mycobacteria from eye infections.Cornea. 2012;31:900–6. 10.1097/ICO.0b013e31823f8bb9 [DOI] [PubMed] [Google Scholar]
• 37.Broda A, Jebbari H, Beaton K, Mitchell S, Drobniewski F. Comparative drug resistance ofMycobacterium abscessus andM. chelonae isolates from patients with and without cystic fibrosis in the United Kingdom.J Clin Microbiol. 2013;51:217–23. 10.1128/JCM.02260-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 38.Zhuo FL, Sun ZG, Li CY, Liu ZH, Cai L, Zhou C, et al. Clinical isolates ofMycobacterium abscessus in Guangzhou area most possibly from the environmental infection showed variable susceptibility.Chin Med J (Engl). 2013;126:1878–83 . [PubMed] [Google Scholar]
• 39.Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene,erm(41), confers inducible macrolide resistance to clinical isolates ofMycobacterium abscessus but is absent fromMycobacterium chelonae.Antimicrob Agents Chemother. 2009;53:1367–76. 10.1128/AAC.01275-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 40.Thomson RM, Carter R, Tolson C, Coulter C, Huygens F, Hargreaves M. Factors associated with the isolation of nontuberculous mycobacteria (NTM) from a large municipal water system in Brisbane, Australia.BMC Microbiol. 2013;13:89. 10.1186/1471-2180-13-89 [DOI] [PMC free article] [PubMed] [Google Scholar]